Endocrine disruptors, aryl hydrocarbon receptor and cortisol secretion.
J Endocrinol Invest
; 47(10): 2407-2419, 2024 Oct.
Article
en En
| MEDLINE
| ID: mdl-38637430
ABSTRACT
PURPOSE:
Endocrine disruptors exert a plethora of effects in endocrine tissues, from altered function to carcinogenesis. Given its lipophilic nature, the adrenal cortex represents an ideal target for endocrine disruptors and thus, possibly, xenobiotic-induced adrenocortical dysfunction. However, there is no clear understanding of the effect of endocrine disruptors on adrenal steroidogenesis, in particular as regards the aryl hydrocarbon receptor (AHR) pathway, one of the key mediators.METHODS:
The present review recapitulates available evidence on the effects of AHR ligands on adrenal steroidogenesis, with focus on cortisol secretion.RESULTS:
Short-term exposure to AHR ligands most often induced a stress-like corticosteroid response followed by decreased responsiveness to stressors with long-term exposure. This was observed in several experimental models across species as well as in animals and humans in real-life settings. Prenatal exposure led to different effects according to sex of the offspring, as observed in murine models and in children from mothers in several countries. In vitro findings proved highly dependent on the experimental setting, with reduced cortisol response and steroidogenic enzyme synthesis mostly observed in fish and increased cortisol synthesis and secretion observed in murine and human adrenal cell lines. Of note, no AHR-binding element was detected in steroidogenic enzyme promoters, suggesting the involvement of additional factors.CONCLUSION:
Our review provides evidence for the impact of AHR ligands on adrenocortical function and indicates further avenues of research to better clarify its effects.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hidrocortisona
/
Receptores de Hidrocarburo de Aril
/
Disruptores Endocrinos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Endocrinol Invest
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Italia